Kim | GGen | YGG ☂️

🩺 Community Question Should preventive healthcare justify large-scale investment and widespread adoption? Viewpoint A: Preventive care involves significant upfront costs and carries risks of overdiagnosis and overtreatment, potentially increasing anxiety and spending without clear mortality gains. Viewpoint B: Prevention through screening and lifestyle interventions can reduce disease burden, hospitalizations, and long-term costs, while improving life expectancy and quality of life. Is prevention a cost-effective long-term strategy or an overextended approach with uncertain net benefit? 👇 Drop A, B, or share your perspective.

🩺 Community Question: Elon Musk recently said that, based on current human constraints, AI-powered robotics could become better surgeons than the best human surgeons within three years at scale. Do you agree with him? Viewpoint A: Agree. With few great surgeons, slow and costly human training, and unavoidable human error, AI and robotics could learn faster and scale surgical skill beyond human limits. Viewpoint B: Disagree. Even acknowledging the human constraints Elon Musk points out, surgery is not only about speed, scale, or error reduction. It also depends on judgment, responsibility, and trust in high-stakes situations, which remain difficult to validate and deploy safely at scale. Is this a near-term breakthrough or a vision that overestimates how quickly surgical autonomy can be safely scaled? 👇 Drop A, B, or share your perspective.

💊 Community Question: Can AI help discover and develop new medicines much faster and cheaper than traditional methods? Viewpoint A: Yes. AI can rapidly test millions of drug ideas, cut early research time and costs dramatically, and in some cases bring medicines to patients years faster. Viewpoint B: Not fully. AI helps at the start, but human trials are still slow, expensive, and unpredictable, keeping overall drug development costly and time-consuming. If AI is expected to change how medicines are made, is the impact already real or mostly promise? 👇 Drop A, B, or share your perspective.

🩺 Community Question Is personalized care realistic for low- and middle-income countries (LMICs), or is it still a model built mainly for high-income countries (HICs)? Viewpoint A: Gradually achievable in LMICs Personalized care can scale over time. Costs of genetic and digital tools are falling, AI-driven insights are becoming more accessible, and hybrid models already work in areas like oncology and chronic care. With the right partnerships and focus, personalization doesn’t have to remain a luxury. Viewpoint B: Not practical for most LMICs For many LMICs, personalized care remains unrealistic. High costs, limited infrastructure, workforce gaps, and unequal access make large-scale adoption difficult. Healthcare systems should prioritize proven, low-cost interventions like vaccination, screening, and basic prevention. Or is the future of healthcare built by combining both approaches? 👇 Drop A, B, or share your perspective. Tag someone who should weigh in on this.

🩺 Community question: Where will the next major breakthrough in healthcare come from? Viewpoint A: From established systems like the US and UK where world-class institutions, funding, and decades of research infrastructure continue to drive innovation. Viewpoint B: From outside traditional power centers where emerging regions, new models, and fewer legacy constraints enable faster experimentation and unexpected breakthroughs. Which side do you believe in and why? 👇 Drop A, B, or share your perspective. Tag someone who should weigh in on this.